UNSPSC 51313215: Bepotastine besilate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25CLN2O3.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W18MO1QR3. European Medicines Agency schedules bepotastine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05778MIG. The term bepotastine besilate is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule bepotastine besilate under HS 29333999 and SITC 51574.

As of Q4 2014, BEPOTASTINE BESILATE remains US FDA's Preferred Term for this commodity. Bepotastine besilate bears US NLM identifiers UMLS ID C1723019 and NCI Concept Code C83550. SMILES: C1CCC(CC1)S(=O)(=O)O.C1CCNC(C1)[C@H](C2CCC(CC2)CL)OC3CCN(CC3)CCCC(=O)O.

UNSPSC 51313215 Bepotastine besilate is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though recent opportunities tagged to this code show limited alignment with the specific drug named. State and local governments buying under this code seek pharmaceutical supplies — including naloxone, generic multi-source drugs, and over-the-counter products — through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves sourcing pharmaceutical inventory to support community health initiatives, emergency response programs, and state employee benefit plans, with vendors required to meet cGMP and DSCSA compliance, maintain relationships with authorized wholesalers, provide detailed product coding and pricing, and carry substantial insurance coverage.

Recent opportunities show activity concentrated in Florida and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling intent to reshape pharmacy benefit contracting beyond traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, seeking generic pharmaceutical and OTC product manufacturers for multi-state distribution through three authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; MMCAP's RFP emphasizes price competitiveness (75 percent of evaluation weight), compliance with cGMP and DSCSA, and flexible pricing models. The code shows limited recent activity overall, and the Seminole County and MMCAP opportunities reflect actual pharmaceutical procurement while the Texas RFI represents exploratory pre-procurement activity.